Academic Journal

Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas

التفاصيل البيبلوغرافية
العنوان: Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas
المؤلفون: Fujita, K., Ichikawa, W., Yamamoto, W., Endo, H., Nagashima, F., Tanaka, R., Miya, T., Araki, K., Kodama, K., Sunakawa, Y., Narabayashi, M., Miwa, K., Ando, Y., Akiyama, Y., Kawara, K., Sasaki, Y.
بيانات النشر: Oxford University Press
سنة النشر: 2009
المجموعة: HighWire Press (Stanford University)
مصطلحات موضوعية: original article
الوصف: Background: S-1 is an oral anticancer agent that combines tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate. The recommended initial dose of S-1 is 120 mg/day for patients with a body surface area (BSA) of ≥1.5 m2 in Japan. Methods: We examined the effects of using this fixed dose on the pharmacokinetics of FT, CDHP, and active 5-fluorouracil (5-FU) on the basis of actual BSA. The pharmacokinetics was compared between patients with a BSA of 1.5–1.75 m2 and those with a BSA of ≥1.75 m2. Results: The median areas under the time–concentration curves (AUCs) of 5-FU and CDHP were significantly lower in patients with a BSA of ≥1.75 m2 than in those with a BSA of 1.5–1.75 m2 ( P = 0.005 and 0.006, respectively; Mann–Whitney U -test). There was no difference between the groups in the median AUC of FT. Conclusion: Systemic exposure to 5-FU is significantly lower in Japanese cancer patients with a large BSA of >1.75 m2 who received the recommended fixed dose of S-1.
نوع الوثيقة: text
وصف الملف: text/html
اللغة: English
Relation: http://annonc.oxfordjournals.org/cgi/content/short/mdn718v1; http://dx.doi.org/10.1093/annonc/mdn718
DOI: 10.1093/annonc/mdn718
الاتاحة: http://annonc.oxfordjournals.org/cgi/content/short/mdn718v1
https://doi.org/10.1093/annonc/mdn718
Rights: Copyright (C) 2009, European Society for Medical Oncology
رقم الانضمام: edsbas.DD28AD88
قاعدة البيانات: BASE